Assistant Professor, Medicine, USC School of Medicine
Oncology
Dr. Tanya B. Dorff, MD
|
|
Give Review
Tanya Dorff practices Oncology. She graduated from David Geffen School of Medicine at UCLA. David Geffen School of Medicine at UCLA is a top medical university. David Geffen School of Medicine at UCLA is ranked 13/7 in Research/PrimaryCare. She has 1 awards "Top Doctors:LA Area". Tanya Dorff is also published. She has 34 publications published. The lastest publication: "Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science.' She accepts Medicare payments and is listed with Medicare.gov.
Publications
- Prostatectomy at high-volume centers improves outcomes and lowers the costs of care for prostate cancer.
- Chemotherapy for Good-Risk Nonseminomatous Germ Cell Tumors: Current Concepts and Controversies.
- Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors.
- Phase I, Dose-Escalation Study of the Targeted Cytotoxic LHRH Analog AEZS-108 in Patients with Castration- and Taxane-Resistant Prostate Cancer.
- New prostate cancer drugs: extending and improving life.
- A Phase II trial of a combination herbal supplement for men with biochemically recurrent prostate cancer.
- Prolonged Fasting Reduces IGF-1/PKA to Promote Hematopoietic-Stem-Cell-Based Regeneration and Reverse Immunosuppression.
- Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer.
- Effect of gender on outcomes following radical cystectomy for urothelial carcinoma of the bladder: A critical analysis of 1,994 patients.
- Epidermal Growth Factor Receptor-targeted Therapy in Squamous Cell Carcinoma of the Penis: A Report of 3 Cases.
- Clinicopathologic Characteristics and Outcomes of Penile Cancer Treated at Tertiary Care Centers in the Western United States.
- Baseline 18F-FDG PET/CT Parameters as Imaging Biomarkers of Overall Survival in Castrate-Resistant Metastatic Prostate Cancer.
- Current role of neoadjuvant and adjuvant systemic therapy for high-risk localized prostate cancer.
- Speeding dating for docetaxel and recent debutantes in castration-resistant prostate cancer: 'plus or minus' may be a minus.
- Management and challenges of corticosteroid therapy in men with metastatic castrate-resistant prostate cancer.
- Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: A retro...
- Prospective Evaluation of 18F-NaF and 18F-FDG PET/CT in Detection of Occult Metastatic Disease in Biochemical Recurrence of Prostate Cancer.
- Blood cells and their use in active immunotherapy of prostate cancer.
- The Epothilones: New Therapeutic Agents for Castration-Resistant Prostate Cancer.
- Factors influencing post-recurrence survival in bladder cancer following radical cystectomy.
- Use of testosterone replacement therapy in patients with prostate cancer.
- Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer.
- Advanced prostate cancer: new agents, new questions.
- Adjuvant Androgen Deprivation for High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921 Study.
- The relationship between proangiogenic gene expression levels in prostate cancer and their prognostic value for clinical outcomes.
- Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patie...
- Perioperative chemotherapy for urothelial cancer: how have we made a "sow's ear" out of a chemotherapy-sensitive tumor?
- Multimarker circulating DNA assay for assessing blood of prostate cancer patients.
- COOPERATIVE GROUP TRIALS - SOUTHWEST ONCOLOGY GROUP (SWOG) INNOVATIONS IN ADVANCED PROSTATE CANCER.
- Successful treatment of metastatic androgen-independent prostate carcinoma in a transsexual patient.
- Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer.
- Ethnic differences in neuroendocrine cell expression in normal human prostatic tissue.
- Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science.
Doctors Specialties
- Oncology
Accepted Insurances
Awards
- Top Doctors:LA Area
Education
-
University of Southern California - LAC+USC Medical Center -
Mount Sinai School of Medicine -
David Geffen School of Medicine at UCLA
Hospital
-
Keck Hospital of USC
Drug Facts
| NPI NUMBER | 1508879115 | |
| NPPES Provider LastName | DORFF | |
| NPPES Provider FirstName | TANYA | |
| NPPES Provider ZIPCode | 900890112 | |
| NPPES Provider State | CA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 1091.0 | |
| Distinct Opioid Count | 4.0 | |
| Opioid Claim Count | 142.0 | |
| Percent Opioid Claims | 13.02 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1508879115 |
| Last Name Of The Provider | DORFF |
| First Name Of The Provider | TANYA |
| View All |
Similar Doctors
|
Dr. Mary E. Sehl, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Shahrooz Eshaghian, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David S. Finley, MD |
|
|
Dr. Neil M. Kogut, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Fariborz Mortazavi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jorge A. Valcarcel, MD |
|
|
Breidi A. Calloway, NP |